Relmada Therapeutics, Inc. (RLMD)Tuesday said it has appointed Raj S. Pruthi as Chief Medical Officer-Urology (CMO).
Pruthi is a physician-scientist with more than 25 years of experience in industry and academic medicine, specializing in urologic oncology, clinical trials, and robotic surgery. Previously, Pruthi was the Chief Medical Officer at enGene Holdings Inc. He also served as Global Medical Affairs leader at Johnson and Johnson Innovative Medicine.
"As we prepare to begin registrational studies, we believe Raj's extensive clinical experience will play a vital role in the NDV-01 programs success, said Sergio Traversa, Chief Executive Officer, Relmada.
The company had reported positive initial Phase 2 data for its lead drug candidate NDV-01 for the treatment of non-muscle invasive bladder cancer (NMIBC) in April this year. Relmada plans to initiate a Phase 3 study of NDV-01 in the first half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.